108 related articles for article (PubMed ID: 32520499)
1. Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT.
Zukotynski KA; Jadvar H; Potvin K; Cho SY; Kim CK; Winquist E
Clin Nucl Med; 2020 Sep; 45(9):727-729. PubMed ID: 32520499
[TBL] [Abstract][Full Text] [Related]
2. Metastasized 18F-DCFPyL-Negative Prostatic Adenocarcinoma Without Neuroendocrine Differentiation.
Broos WAM; Kocken M; van der Zant FM; Knol RJJ; Wondergem M
Clin Nucl Med; 2018 Feb; 43(2):120-122. PubMed ID: 29261618
[TBL] [Abstract][Full Text] [Related]
3. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
4. 18F-DCFPyL Uptake in an Incidentally Detected Follicular Lymphoma by PET/CT Performed for Biochemically Recurrent Prostate Cancer.
Meijer D; Wondergem M; Knol RJJ; Broos WAM; van der Zant FM
Clin Nucl Med; 2020 Feb; 45(2):e96-e97. PubMed ID: 31361646
[TBL] [Abstract][Full Text] [Related]
5. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases.
Perez PM; Hope TA; Behr SC; van Zante A; Small EJ; Flavell RR
Clin Nucl Med; 2019 Jan; 44(1):e28-e32. PubMed ID: 30394930
[TBL] [Abstract][Full Text] [Related]
6. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
7. A Comparison of
Fourquet A; Rosenberg A; Mena E; Shih JJ; Turkbey B; Blain M; Bergvall E; Lin F; Adler S; Lim I; Madan RA; Karzai F; Gulley JL; Dahut WL; Wood BJ; Chang R; Levy E; Choyke PL; Lindenberg L
J Nucl Med; 2022 May; 63(5):735-741. PubMed ID: 34475237
[No Abstract] [Full Text] [Related]
8. Concomitant Prostate Carcinoma and Follicular Lymphoma: "Flip-Flop" Appearances on PSMA and FDG PET/CT Scans.
Dhiantravan N; Hovey E; Bosco A; Wegner EA
Clin Nucl Med; 2019 Oct; 44(10):797-798. PubMed ID: 31348079
[TBL] [Abstract][Full Text] [Related]
9. Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.
Cornelis FH; Durack JC; Morris MJ; Scher HI; Solomon SB
Clin Nucl Med; 2017 Dec; 42(12):e516-e518. PubMed ID: 29099733
[TBL] [Abstract][Full Text] [Related]
10. Primary Peripheral Primitive Neuroectodermal Tumor of the Prostate on 18F-DCFPyL PET/CT.
Liu Y; Xu B
Clin Nucl Med; 2020 May; 45(5):e249-e251. PubMed ID: 32149795
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. 18F-PSMA-1007 Uptake in Pulmonary Lymphangitic Carcinomatosis Metastasis From Prostate Cancer.
Liu BL; Hong JJ; Tang K; Lin J; Zheng XW
Clin Nucl Med; 2021 Jul; 46(7):e355-e357. PubMed ID: 33782286
[TBL] [Abstract][Full Text] [Related]
13. Intraindividual Comparison of
Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
[TBL] [Abstract][Full Text] [Related]
14. Early lesion detection with
Wondergem M; Jansen BHE; van der Zant FM; van der Sluis TM; Knol RJJ; van Kalmthout LWM; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1911-1918. PubMed ID: 31230088
[TBL] [Abstract][Full Text] [Related]
15. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
16. Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.
Rowe SP; Gorin MA; Hammers HJ; Pomper MG; Allaf ME; Javadi MS
Clin Nucl Med; 2016 Jan; 41(1):83-5. PubMed ID: 26402128
[TBL] [Abstract][Full Text] [Related]
17. Increased PSMA Expression in Castration-Resistant Prostate Cancer Metastases 3 Months After Initiation of Enzalutamide Indicated by 18F-DCFPyL PET/CT.
Wondergem M; van der Zant F; Broos W; Knol R
Clin Nucl Med; 2019 Jul; 44(7):582-584. PubMed ID: 31058686
[TBL] [Abstract][Full Text] [Related]
18. Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations.
Zukotynski KA; Valliant J; Bénard F; Rowe SP; Kim CK; Pomper MG; Cho SY
Clin Nucl Med; 2018 Mar; 43(3):213-216. PubMed ID: 29356735
[TBL] [Abstract][Full Text] [Related]
19. Unusual Metastatic Prostate Cancer in Subcarinal Lymph Node and Peritoneal Nodule Found on 18 F-PSMA PET/CT With Rising PSA of 0.4 ng/mL.
Gao M; Lu Y
Clin Nucl Med; 2022 Nov; 47(11):989-990. PubMed ID: 35619200
[TBL] [Abstract][Full Text] [Related]
20. Splenic Hemangioma as a Potential Pitfall on PSMA-Targeted 18F-DCFPyL PET/CT.
Chaussé G; Laufer J; Abikhzer G; Probst S
Clin Nucl Med; 2019 Mar; 44(3):255-256. PubMed ID: 30589670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
